Search Result
Results for "
Factor Xa
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-10268S
-
|
Factor Xa
|
Cardiovascular Disease
|
Betrixaban-d6 is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor[1].
|
-
-
- HY-119124
-
D21-2393
|
Drug Metabolite
|
Metabolic Disease
|
Edoxaban M4, an active metabolite of Edoxaban, shows reproducible, but concentration-dependent matrix effects. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor .
|
-
-
- HY-50667S
-
BMS-562247-01-13C,d3
|
Factor Xa
|
Cardiovascular Disease
|
Apixaban- 13C,d3 is a deuterium and 13C labeled Apixaban. Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively[1].
|
-
-
- HY-12605
-
|
Thrombin
|
Metabolic Disease
|
SAR107375 is a potent and orally active dual thrombin and factor Xa inhibitor, with Ki values of 1 nM and 8 nM for factor Xa and thrombin, respectively .
|
-
-
- HY-10777
-
|
Factor Xa
|
Cardiovascular Disease
|
EMD 495235 is a potent and orally active coagulation factor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM. EMD 495235 shows anticoagulant activities .
|
-
-
- HY-18660
-
PER977
|
Factor Xa
|
Cardiovascular Disease
|
Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
|
-
-
- HY-50667
-
BMS-562247-01
|
Factor Xa
|
Cardiovascular Disease
|
Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
|
-
-
- HY-76971
-
|
Factor Xa
|
Cardiovascular Disease
|
Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a Ki of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC50s of 2.1 nM and 92 nM, respectively .
|
-
-
- HY-B0597
-
-
-
- HY-11091
-
BMS 561389 hydrochloride; DPC 906 hydrochloride
|
Factor Xa
Thrombin
|
Cardiovascular Disease
|
Razaxaban hydrochloride (BMS 561389 hydrochloride) is a highly potent, selective and orally active factor Xa inhibitor with a Ki of 0.19 nM. Razaxaban hydrochloride exhibits excellent selectivity (>5000-fold) for factor Xa over other related serine proteases. Razaxaban hydrochloride is also a potent thrombin inhibitor with a Ki of 540 nM. Razaxaban hydrochloride has strongly antithrombotic activity .
|
-
-
- HY-11090A
-
-
-
- HY-P3126
-
|
Factor Xa
|
Others
|
Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride is a factor Xa specific chromogenic substrate .
|
-
-
- HY-153829
-
-
-
- HY-B0597R
-
Fondaparin sodium (Standard); SR-90107A (Standard)
|
Factor Xa
|
Cardiovascular Disease
Cancer
|
Fondaparinux (sodium) (Standard) is the analytical standard of Fondaparinux (sodium). This product is intended for research and analytical applications. Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
|
-
-
- HY-B0385
-
FOY
|
Proteasome
Factor Xa
|
Inflammation/Immunology
|
Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .
|
-
-
- HY-17567A
-
Sodium heparin; Sodium heparinate
|
Thrombin
Factor Xa
Autophagy
|
Cardiovascular Disease
Cancer
|
Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa. Heparin sodium salt significantly inhibits exosome-cell interactions.
|
-
-
- HY-153817
-
|
Factor Xa
|
Cardiovascular Disease
|
FXIa-IN-13 (example 1) is an Factor Xa inhibitor with antithrombotic activity. FXIa-IN-13 inhibits arteriovenous thrombosis in vivo and in vitro .
|
-
-
- HY-P4576
-
|
Factor Xa
|
Others
|
Methoxycarbonyl-D-Nle-Gly-Arg-pNA is a synthetic trypsin that can serve as a substrate for coagulation factors IXa (FIXa) and Xa (FXa) .
|
-
-
- HY-19373
-
3DP-10017
|
Thrombin
Factor Xa
|
Cardiovascular Disease
|
RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.
|
-
-
- HY-10268
-
PRT054021
|
Factor Xa
|
Cardiovascular Disease
|
Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect .
|
-
-
- HY-10268B
-
PRT054021 hydrochloride
|
Factor Xa
|
Cardiovascular Disease
|
Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect .
|
-
-
- HY-10268A
-
PRT054021 maleate
|
Factor Xa
|
Cardiovascular Disease
|
Betrixaban (PRT054021) maleate is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban maleate shows antithrombotic effect .
|
-
-
- HY-W018781
-
|
Ser/Thr Protease
|
Cancer
|
Benzamidine hydrochloride is a trypsin-like serine proteases with Kis of 20, 21, 97, 110, 320 and 750 μM against Tryptase, Trypsin, uPA, Factor Xa, Thrombin and tPA, respectively .
|
-
-
- HY-50903
-
Rivaroxaban
Maximum Cited Publications
14 Publications Verification
BAY 59-7939
|
Factor Xa
|
Cardiovascular Disease
Cancer
|
Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM) .
|
-
-
- HY-100655
-
|
Drug Metabolite
|
Cardiovascular Disease
|
O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively .
|
-
-
- HY-18660B
-
PER977 acetate
|
Factor Xa
|
Cardiovascular Disease
|
Ciraparantag (PER977) acetate is a thrombin and factor Xa inhibitor. Ciraparantag acetate is a broad-spectrum reversal agent for anticoagulants, including low molecular weight heparins, unfractionated heparins, and some direct oral anticoagulants, but not VKAs.
|
-
-
- HY-17567C
-
Sodium heparin (MW 15kDa); Sodium heparinate (MW 15kDa)
|
Thrombin
Factor Xa
Autophagy
|
Cardiovascular Disease
|
Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa .
|
-
-
- HY-W087937
-
Benzenecarboximidamide hydrochloride hydrate
|
Ser/Thr Protease
|
Cancer
|
Benzamidine (Benzenecarboximidamide) hydrochloride hydrate is a reversible competitive trypsin-like serine proteases inhibitor with Kis of 20, 21, 97, 110, 320 and 750 μM against Tryptase, Trypsin, uPA, Factor Xa, Thrombin and tPA, respectively .
|
-
-
- HY-153480
-
BAX499
|
Factor Xa
|
Others
|
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
|
-
-
- HY-153480A
-
BAX499 sodium
|
Factor Xa
|
Others
|
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
|
-
-
- HY-76948
-
|
Factor Xa
|
Cardiovascular Disease
|
5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
|
-
-
- HY-50903S
-
BAY 59-7939-d4
|
|
|
Rivaroxaban-d4 is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent,selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM)[1][2].
|
-
-
- HY-122592
-
|
Factor Xa
|
Cardiovascular Disease
|
Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .
|
-
-
- HY-14853
-
YM150
|
Factor Xa
Ser/Thr Protease
|
Cardiovascular Disease
|
Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects .
|
-
-
- HY-134686
-
|
Factor Xa
Thrombin
|
Cardiovascular Disease
|
Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention .
|
-
-
- HY-114015
-
|
Ser/Thr Protease
|
Cancer
|
APC-6860 is a trypsin-like serine proteases inhibitor with ki values of 0.21 and 0.44 μM for uPA and trypsin, respectively. APC-6860 has a selectivity ratio for tPA versus uPA of 80. APC-6860 has ki values of 0.1 and 0.082 μM for human and murine urokinases, respectively. APC-6860 can be used for the research of cancer .
|
-
-
- HY-P2185
-
|
MMP
|
Others
|
NFF-3, the peptide, is a selective MMP substrate. NFF-3 selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .
|
-
-
- HY-P2185A
-
|
MMP
|
Others
|
NFF-3 TFA, the peptide, is a selective MMP substrate. NFF-3 TFA selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 TFA is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 TFA with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .
|
-
-
- HY-10264
-
DU-176
|
Factor Xa
Thrombin
|
Cardiovascular Disease
Cancer
|
Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .
|
-
-
- HY-10264B
-
DU-176b monohydrate
|
Factor Xa
Thrombin
|
Cardiovascular Disease
Cancer
|
Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .
|
-
-
- HY-10264A
-
DU-176b
|
Factor Xa
Thrombin
|
Cardiovascular Disease
Cancer
|
Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .
|
-
-
- HY-10264C
-
DU-176 hydrochloride
|
Factor Xa
Thrombin
|
Cardiovascular Disease
|
Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research .
|
-
-
- HY-50667S1
-
BMS-562247-01-d3
|
Isotope-Labeled Compounds
|
Others
|
Apixaban-d3 (BMS-562247-01-d3)is the deuterium labeledApixaban(HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
|
-
-
- HY-10264S
-
DU-176-d6
|
Factor Xa
Thrombin
|
Cardiovascular Disease
|
Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .
|
-
-
- HY-109509
-
PK 10169; EnoXaparin sodium; Lovenox
|
Factor Xa
Thrombin
SARS-CoV
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19 .
|
-
-
- HY-P6023
-
|
Factor Xa
|
Cardiovascular Disease
|
D-Leu-Pro-Arg-Rh110-D-Pro is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro can be used to detect FXIa activity .
|
-
-
- HY-P6023B
-
|
Factor Xa
|
Cardiovascular Disease
|
D-Leu-Pro-Arg-Rh110-D-Pro acetate is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro acetate consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro acetate can be used to detect FXIa activity .
|
-
-
- HY-P6023A
-
|
Factor Xa
|
Cardiovascular Disease
|
D-Leu-Pro-Arg-Rh110-D-Pro TFA is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro TFA consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro TFA can be used to detect FXIa activity .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-P2185
-
|
Dyes
|
NFF-3, the peptide, is a selective MMP substrate. NFF-3 selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .
|
Cat. No. |
Product Name |
Type |
-
- HY-W087937
-
Benzenecarboximidamide hydrochloride hydrate
|
Biochemical Assay Reagents
|
Benzamidine (Benzenecarboximidamide) hydrochloride hydrate is a reversible competitive trypsin-like serine proteases inhibitor with Kis of 20, 21, 97, 110, 320 and 750 μM against Tryptase, Trypsin, uPA, Factor Xa, Thrombin and tPA, respectively .
|
-
- HY-P3009
-
|
Biochemical Assay Reagents
|
Factor Xa is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3126
-
|
Factor Xa
|
Others
|
Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride is a factor Xa specific chromogenic substrate .
|
-
- HY-P2185A
-
|
MMP
|
Others
|
NFF-3 TFA, the peptide, is a selective MMP substrate. NFF-3 TFA selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 TFA is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 TFA with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .
|
-
- HY-P3009
-
|
Peptides
|
Others
|
Factor Xa is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-P4576
-
|
Factor Xa
|
Others
|
Methoxycarbonyl-D-Nle-Gly-Arg-pNA is a synthetic trypsin that can serve as a substrate for coagulation factors IXa (FIXa) and Xa (FXa) .
|
-
- HY-P2185
-
|
MMP
|
Others
|
NFF-3, the peptide, is a selective MMP substrate. NFF-3 selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .
|
-
- HY-P6023
-
|
Factor Xa
|
Cardiovascular Disease
|
D-Leu-Pro-Arg-Rh110-D-Pro is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro can be used to detect FXIa activity .
|
-
- HY-P6023B
-
|
Factor Xa
|
Cardiovascular Disease
|
D-Leu-Pro-Arg-Rh110-D-Pro acetate is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro acetate consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro acetate can be used to detect FXIa activity .
|
-
- HY-P6023A
-
|
Factor Xa
|
Cardiovascular Disease
|
D-Leu-Pro-Arg-Rh110-D-Pro TFA is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro TFA consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro TFA can be used to detect FXIa activity .
|
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-10268S
-
|
Betrixaban-d6 is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor[1].
|
-
-
- HY-50667S
-
|
Apixaban- 13C,d3 is a deuterium and 13C labeled Apixaban. Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively[1].
|
-
-
- HY-10264S
-
|
Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .
|
-
-
- HY-50667S1
-
|
Apixaban-d3 (BMS-562247-01-d3)is the deuterium labeledApixaban(HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
|
-
Cat. No. |
Product Name |
Application |
Reactivity |
-
- HY-P81604
-
Activated Factor Xa heavy chain; Coagulation Factor X; F10; Factor Xa; FXa; Prothrombinase; Stuart Factor
|
WB, IHC-P
|
Human |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: